BIOCORP announced the signature of a contract with HRA Pharma (an affiliate of the global consumer self-care leader Perrigo Company plc). This agreement concerns the development and industrialization of an innovative medical device aiming to provide instant relief and faster healing of skin injuries. After an initial concept and feasibility study conducted by BIOCORP, the two parties entered into an initial development agreement to design, test and validate a device in compliance with MDR (E.U. Medical Device Regulation) and FDA (U.S. Food and Drug Administration) requirements.

BIOCORP will oversee the industrialization of this new device and the qualification of the manufacturing, filling, and packaging services within its plant in Issoire. According to the terms of the exclusive agreement, worth in the lower single-digit millions region, BIOCORP will receive an initial milestone payment this year, followed by further payments based on progress from 2024 onwards.